Pliant Therapeutics, Inc. Stock: price and insider trades · United States
Pliant Therapeutics, Inc.: what insiders have been doing
Pliant Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 23 October 2025 to 23 October 2026, the disclosure feed for Pliant Therapeutics, Inc. logged 4 filings by 4 insiders.
Only sales appear on the open market, 4 sales in all totalling €141k, filed by 4 insiders. Coulie Bernard filed the largest sale, €98k, on 22 January 2026, which represents 0.18% of the company's market value.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 4 filings, this issuer sits below that mark. Looking back to 2020, when coverage begins, insiders filed no purchases and 103 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -149.3 m USD.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+1 other insider
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 6,917 shares@ US$1.280.014% mcap100.0% of flowCommon StockSEC:0001746473-26-000008:0
- 24,002 shares@ US$1.280.048% mcap2.1% of flowCommon StockSEC:0001746473-26-000012:0
- 7,534 shares@ US$1.280.015% mcap16.9% of flowCommon StockSEC:0001746473-26-000010:0
- 89,375 shares@ US$1.280.18% mcap2.5% of flowCommon StockSEC:0001746473-26-000009:0
- 35,000 shares0Common StockSEC:0001746473-25-000017:0
- 45,650 shares0Common StockSEC:0001746473-25-000013:0
- 56,650 shares0Common StockSEC:0001746473-25-000011:0
- 162,500 shares0Common StockSEC:0001746473-25-000009:0
- 25,875 shares0Common StockSEC:0001746473-25-000019:0
- 40,150 shares0Common StockSEC:0001746473-25-000015:0
- 10,230 shares@ US$10.9911.1% of flowCommon StockSEC:0001746473-25-000001:1
- 15,936 shares@ US$11.201114.6% of flowCommon StockSEC:0001746473-25-000004:0
- 18,478 shares@ US$11.20115.5% of flowCommon StockSEC:0001746473-25-000003:0
- 20,148 shares@ US$11.201117.5% of flowCommon StockSEC:0001746473-25-000005:0
- 52,419 shares@ US$11.201114.6% of flowCommon StockSEC:0001746473-25-000006:0
- 13,270 shares@ US$11.201116.6% of flowCommon StockSEC:0001746473-25-000001:0
- 3,740 shares@ US$11.201183.1% of flowCommon StockSEC:0001746473-25-000002:0
- 10,911 shares@ US$11.569.3% of flowCommon StockSEC:0001746473-24-000125:0
- 7,656 shares@ US$11.569.4% of flowCommon StockSEC:0001746473-24-000121:0
- 12,319 shares@ US$11.563.6% of flowCommon StockSEC:0001746473-24-000129:0
- 38,710 shares@ US$11.5610.6% of flowCommon StockSEC:0001746473-24-000123:0
- 9,900 shares@ US$11.568.9% of flowCommon StockSEC:0001746473-24-000127:0
- 14,954 shares0Common StockSEC:0001746473-24-000111:0
- 21,313 shares0Common StockSEC:0001746473-24-000115:0
- 75,625 shares0Common StockSEC:0001746473-24-000113:0
25 of 190 declarations
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (ticker: PLRX) is a United States–based biopharmaceutical company listed on the NASDAQ market. Headquartered in South San Francisco, California, and incorporated in Delaware in June 2015, the company is a clinical-stage developer built around a proprietary integrin biology platform. Its core strategy is to discover and develop therapeutics that modulate integrin-mediated pathways, with an initial emphasis on fibrosis biology and broader applications in oncology and other tissue-based diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000080/plrxannualreport.pdf?utm_source=openai))
Pliant initially gained investor attention through bexotegrast, its lead candidate in idiopathic pulmonary fibrosis (IPF), a serious progressive lung disease with a high unmet medical need. In 2025, however, the company announced that it was discontinuing bexotegrast development in IPF following a safety review and an unfavorable risk-benefit assessment. That decision materially changed the company’s profile and led to a strategic restructuring, including lower operating costs and a leaner organization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647325000150/plrx-20250630.htm?utm_source=openai))
Read moreShow less
Scientifically, Pliant’s differentiation lies in its integrin-focused drug discovery engine. Management has described the platform as having broad applicability across multiple disease areas, and the company has also highlighted a tissue-targeted delivery approach that uses cell-specific integrin receptors to deliver payloads such as siRNAs to selected tissues. This makes Pliant more than a single-asset story; it is a platform company whose longer-term value depends on whether its discovery engine can produce multiple clinically meaningful programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001746473/000174647326000037/plrx-20251231.htm?utm_source=openai))
From a competitive standpoint, PLRX remains a development-stage biotech with no commercial product revenues, so its investment case is driven by clinical data, regulatory progress, capital efficiency, and the company’s ability to pivot after setbacks. Following the discontinuation of the IPF program, Pliant has communicated plans to accelerate PLN-101095, with a Phase 1b indication expansion trial planned in 2026 for NSCLC and other tumor types with a mechanistic rationale for integrin inhibition. That pipeline evolution is important because it suggests the company is trying to reuse its scientific platform in new therapeutic settings rather than relying on a single pulmonary fibrosis asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/plrx-20251231.htm?utm_source=openai))
Geographically, the business is primarily US-centric, with corporate and operational activity in South San Francisco, California. For French-speaking investors, PLRX is therefore best understood as a US Nasdaq-listed specialty biotech with a high-risk/high-upside profile, where recent SEC filings and insider Form 4 activity are part of the normal disclosure stream that investors follow closely. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000080/plrxannualreport.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
